Desensitization of the Neurokinin 1 Receptor Is Mediated by the Receptor Carboxy-Terminal Region, but Is Not Caused by Receptor Internalization

Abstract: The carboxy-terminal cytoplasmic regions of the rat neurokinin 1 (substance P) and neurokinin 2 (neurokinin A) receptors have been exchanged to determine if this region of the neurokinin 1 receptor is involved in its desensitization. When expressed at similar levels in stably transfected Chinese hamster ovary (CHO) cell lines, receptors containing the carboxy-terminal region of the neurokinin 1 receptor desensitized significantly more (as measured by reduction of the inositol 1,4,5-trisphosphate response) when preexposed for 1 min to 1 µ M neurokinin, indicating a role for the carboxy-terminal region of the neurokinin 1 receptor in its desensitization. Measurement of receptor internalization using radiolabeled neurokinins (0.3 n M ) indicated that ∼75–80% of the receptors were internalized in each cell line after 10 min at 37°C, with no observable correlation between neurokinin receptor desensitization and internalization. Measurement of loss of receptor surface sites for cell lines CHO NK1 and CHO NK1NK2 following exposure to 1 µ M substance P also indicated no obvious relationship between the percent desensitization and percent of receptors internalized. Also, two inhibitors of neurokinin 1 receptor internalization, phenylarsine oxide and hyperosmolar sucrose, did not inhibit neurokinin 1 receptor desensitization. The protein kinase inhibitors Ro 31-8220, staurosporine, and Zn²⁺ had no effect on neurokinin 1 receptor desensitization, indicating that the kinases affected by these agents are not rate-limiting in neurokinin 1 receptor desensitization in this system.     

Sulfoxide configuration in sparsomycin determines time-dependent and competitive inhibition of peptidyl transferase

Sparsomycin, S_cR_s configuration, was the most potent of the four possible stereoisomers as a competitive inhibitor of peptide bond formation. In addition, the configuration of the two chiral centers dictated whether the compound exhibited time- and temperature-dependent inhibition of peptidyl transferase when incubated with polysomes prior to enzyme assay. The data corroborate the thesis that a peptidyl transferase-mediated acylation of the pivotal sulfoxide moiety and subsequent Pummerer rearrangement play a significant role in the inhibitory properties of sparsomycin.     

A model of gradient interpretation based on morphogen binding

We propose a model in which pattern formation is controlled by several concentration gradients of “morphogens” and by allosteric proteins which bind them. In this model, each protein can bind up to two molecules of each morphogen and has an “active state” when one molecule of each morphogen is bound. The concentration of the active state of such a “morphogen binding protein” varies with position in a way that depends on the values given the binding constants. In a contour map of the active state concentration, the contours can have a variety of simple shapes.Simply-shaped regions of cell differentiation can be defined directly by concentration contours of a morphogen binding protein using a threshold-sensing mechanism. More complex shapes may be generated using several proteins and a “winner-take-all” rule according to which each protein specifies some particular sort of cell differentiation and the differentiation of cells in any position is governed by the protein with the highest active state concentration.We present an application of our model to the vertebrate limb skeleton; we use the “winner-take-all” mechanism and thirteen morphogen binding proteins, eleven of which specify cartilage formation. In this model we use one morphogen binding protein to specify the shaft of a typical long bone and one for each epiphysis. Our model is reasonably successful in imitating the in vivo positions and orientations of developing bones and in generating simple, plausible-looking articular surfaces.In addition to the morphogen-binding model we propose a mechanism which could transform morphogen-binding patterns into high-amplitude patterns capable of controlling the activity of structural genes. This “amplifying mechanism” can account for two previously unexplained features of limb skeletal development: the early formation of the diffusely-bounded “scleroblastema” in the limb bud and the center-to-edge gradations in cartilage formation rate which are later seen within individual chondrification foci.A simple modification of the morphogen-binding model provides an explanation for the general anatomical phenomenon of metamerism: The model can account for the formation of inexactly repeating patterns (such as the pattern of the vertebral column) and suggests a mechanism by which such patterns could (1) evolve from exactly repeating patterns, and (2) acquire, in further evolution, a high degree of specialization of the individual repeating units.The most promising approach for testing the morphogen-binding model would appear to involve experiments in which cytoplasm is transferred between cells at various stages of pattern development. Support for the model could also come from the discovery of certain kinds of hereditary limb defects.     

Phosphorus-31 nuclear magnetic resonance studies of wild-type and glycolytic pathway mutants of Saccharomyces cerevisiae.

High-resolution phosphorus-31 nuclear magnetic resonance (31P NMR) spectra of wild-type and mutant strains of Saccharomyces cerevisiae were observed at a frequency of 145.7 MHz. Levels of various phosphorus metabolites were investigated upon addition of glucose under both aerobic and anaerobic conditions. Three mutant strains were isolated and their biochemical defects characterized: pfk lacked phosphofructokinase activity; pgi lacked phosphoglucose isomerase activity; and cif had no glucose catabolite repression of the fructose bisphosphatase activity. Each mutant strain was found to accumulate characteristic sugar phosphates when glucose was added to the cell suspension. In the case of the phosphofructokinase deficient mutant, the appearance of a pentose shunt metabolite was observed. 31P NMR peak assignments were made by a pH titration of the acid extract of the cells. Separate signals for terminal, penultimate, and central phosphorus atoms in intracellular polyphosphates allowed the estimation of their average molecular weight. Signals for glycero(3)phosphochline, glycero(3)phosphoserine, and glycero(3) phosphoethanolamine as well as three types of nucleotide diphosphate sugars could be observed. The intracellular pH in resting and anaerobic cells was in the range 6.5--6.8 and the level of adenosine 5'-triphosphate (ATP) low. Upon introduction of oxygen, the ATP level increased considerably and the intracellular pH reached a value of pH 7.2--7.3, irrespective of the external medium pH, indicating active proton transport in these cells. A new peak representing the inorganic phosphate of one of the cellular organelles, whose pH differed from the cytoplasmic pH, could be detected under appropriate conditions.     

Postribosomal complexes containing eukaryotic initiation factor eIF-2

Eukaryotic initiation factors are found in the postribosomal supernatant as well as bound to the 40S ribosomal subunits. We have analyzed the factor activities from the supernatant by means of zonal centrifugation followed by Sepharose-heparin affinity chromatography. They exist both as free factors, sedimenting in a broad range from 4 to 7S, and complexed with other protein(s) with a sedimentation value of 16–20S. This complexed fraction contains besides eIF-2 another activity which exhibits a profound stimulation on amino acid incorporation in crude lysates and appears to counteract the heme-regulated inhibitor.Abbreviations eIF-2, eIF-3, eIF-4A and eIF-4B are eukaryotic initiation factors, see FEBS Letters 76, 1-10 (1977).     

Stimulation of human vascular endothelial cell growth by a platelet-derived growth factor and thrombin

Repair of a vascular wound is mediated by migration and subsequent replication of the endothelial cells that form the inner lining of blood vessels. We have measured the growth response of human umbilical vein endothelial cells (HuE) to two polypeptides that are transiently produced in high concentrations at the site of a wound; the platelet-derived growth factor (PDGF) and the protease thrombin. When 10⁴ HuE cells are seeded as a dense island (2-mm diameter) in the center of a 16-mm tissue culture well in medium containing 20% human serum derived from platelet-poor plasma (PDS), no increase in cell number or colony size is observed. With the addition of 0.5 ng/ml partially purified PDGF, colony size increases and the number of cells after 8 days is 4.8 × 10⁴. When human thrombin (1 μg/ml) is added along with the PDGF, the cell number rises to 9.2 × 10⁴. Thrombin alone stimulates no increase in cell number. Although partially purified PDGF stimulates endothelial cells maintained in PDS as well as those maintained in whole blood serum (WBS), pure PDGF is active only when assayed in medium that contains WBS and is supplemented with thrombin. These results suggest the existence of a second class of platelet-derived factors that enable HuE cells to respond to the mitogenic activity of the purified platelet mitogen and thrombin.     

Chemospecific deuteration of prostaglandin silyl ethers

Complete chemical selectivity ( , chemospecificity) has been achieved in the homogeneous deuteration of C₅---C₆ and endocyclic C₁₀---C₁₁ prostaglandin double bonds without rearrangement or partial reduction of C₁₃---C₁₄ or C₈---C₁₂ double bonds. The homogeneous deuteration reaction utilizes protection of the C₁₃---C₁₄ double bond as the C₁₅ O-silyl ether and protection of the carboxyl group as the methyl ester prior to reduction under molecular deuterium with tris(triphenylphosphine)chlororhodium (I) (Wilkinson's catalyst) in 60:40 acetone:benzene at 25°C. The reaction has been used to prepare six specifically deuterated prostaglandins: 5,6-dideuterio-PGF_1α, 5,6-dideuterio-PGE₁, 5,6-dideuterio-PGB₁, 3,3,4,4,5,6-hexadeuterio-PGF_1α, 5,6,10,11-tetradeuterio-11-deoxy-PGE₁, and 10,11-dideuterio-11-deoxy-PGE₁.